Introduction Venous thromboembolic disease is a serious complication of total hip replacement (THR). Use of low-molecular-weight heparin (LMWH) has been shown to reduce the occurrence of deep-vein thrombosis (DVT) significantly, but side effects such as bleeding and thrombocytopenia are frequent. Pneumatic compression with foot-pumps seems to provide the best balance of effectiveness and safety. However, a recent meta-analysis showed that the overall number of patients investigated in randomised clinical trials is too small to draw evidence-based conclusions regarding mechanical prophylaxis of DVT. This trial is a contribution in comparing the effectiveness and safety of mechanical versus chemical prophylaxis of DVT in patients managed with THR. Methods Inclusion criteria were hip osteoarthritis, age less than 80 years, and uninterrupted use of a foot-pump. Exclusion criteria were a history of thromboembolic disease, heart disease, malignancy and bleeding diatheses. Two hundred and sixteen consecutive patients were considered for inclusion in the trial and were randomized either for management with (LMWH) (Fraxiparin, Sanofi -Synthelabo, France) or with the A-V Impulse foot-pump (Orthofix Vascular Novamedix, UK). All patients started mobilisation on crutches with partial weight-bearing on day two using compression stockings. The foot-pump was applied on both feet in the recovery room and was used until patient discharge. Management with the foot-pump was interrupted only during physiotherapy and toileting. A reverse Trendelenburg position (head-high, feet-low) was applied at rest to enhance the pneumatic effect of the pumps. Patients were monitored for DVT using serial duplex sonography (Sonoline Elegra, Siemens, Germany) at day three, 10 and 45 after surgery. Results DVT was detected in three of 100 patients managed with the foot-pump compared with six of 100 patients who received chemical prophylaxis. Sixteen patients did not tolerate continuous use of the foot-pump and were excluded from the study. The average post-operative drainage was 259 ml in the foot-pump group and 328 ml in the control group (p=0.05). Patients with foot-pump had less swelling of the thigh (10 mm compared with 15 mm) (p=0.05). One patient developed heparin-induced thrombocytopenia. Conclusions This study confirms the effectiveness and safety of mechanical prophylaxis of DVT in THR, confirming the outcomes of previous randomized clinical trials. Some patients cannot tolerate the foot-pump, mostly because of sleep disturbance. In relation to the conduct of this study, one or more of the authors is in receipt of a research grant from a non-commercial source

Recently, the International Consensus Statement Group reported that mechanical prophylaxis with foot-pumps should be considered “Grade A” recommendation for prevention of deep-vein thrombosis after total hip replacement. Mechanical prophylaxis with foot-pumps provides an interesting alternative to chemical agents in the prevention of thomboembolic disease following major orthopaedic surgery procedures. Recent duplex ultrasound studies have suggested that simultaneous use of graduated compression stockings (GCS) may hinder the pneumatic compression effect of foot pumps. The hypothesis of this prospective study was that the use of foot-pumps without GCS does not affect the efficacy of DVT prophylaxis, and improves patient compliance. 846 consecutive patients admitted at a single institution undergoing total hip (THR) or knee replacement (TKR) were included in the study. The A-V Impulse System® foot-pump units (Orthofix Vascular Novame-dix, Andover, UK) was used in all patients. Forty-six patients discontinued the use of foot-pumps, leaving 400 patients who received foot-pumps in combination with GCS and 400 patients with foot pumps alone. Eleven patients of the stocking group (2.7%) and 9 patients of the no-stockings group (2.3%) developed postoperative symptomatic DVT (p=0.07). DVT was more frequent in TKR (10 of 364; 2.7%) than in THR (10 of 436; 2.3%). Non-fatal pulmonary embolism occurred in 4 patients out of 20 with symptomatic DVT, 2 each of the stockings and no stockings groups. The foot pump discontinuation rate of patients treated with stockings was 7%, versus 4% of patients treated without stockings (p< 0.05). In conclusion, management of patients with foot-pumps without GCS does not reduce efficacy of DVT prophylaxis after THR and TKR, and improves patient compliance

Introduction: Large numbers of women are taking hormone replacement therapy (HRT) or an oestrogen containing contraceptive pill. They are being advised that these medications can increase their risk of developing deep vein thrombosis (DVT) and there has been considerable recent publicity.

Aim: To determine the practice of New Zealand orthopaedic surgeons when women taking such medications present for major surgery.

Method: A postal survey was sent to all New Zealand orthopaedic surgeons. The current practice was compared with recently revised national guidelines and manufacturers advice.

Results: The response rate was 80% (118/148). There was wide variation in the beliefs surrounding the peri-operative use of both of these medications. Of the surgeons who replied, 44% indicated that they would routinely advise discontinuing the combined oral contraceptive pill peri-operatively for major surgery, 24% indicated that they would routinely advise discontinuing HRT peri-operatively. The mean duration that surgeons would discontinue the medication pre-operatively was 13 days for the contraceptive pill and nine days for HRT. The mean time for re-starting medication post-operatively was 18 days for the contraceptive pill and 13 days for HRT.

Recently released New Zealand guidelines recommend that HRT should be stopped for at least 30 days prior to elective surgery and withheld for 90 days following surgery. Less than 3% of surgeons appeared to be routinely following this recommendation. Most manufacturers of combined oral contraceptive pills recommend stopping the medication for at least four weeks prior to elective surgery. Only 25% of surgeons routinely practice in accordance with these recommendations.

Discussion: This survey demonstrated substantial differences between actual clinical practice, recently revised national guidelines and manufacturers’ advice. These differences need to be brought to the attention of surgeons and guideline producers alike. A review of international literature and recommendations revealed that these guidelines are very conservative and that strong evidence for them is lacking. Issues to be considered include the practicalities of implementing such recommendations; the associated risks of discontinuing medication; the presence of other risk factors; the type of surgery; the use of thromboprophylaxis and not least the wishes of the patient. The possible medico-legal implications are uncertain and caution in this area is advised.

Mechanical prophylaxis with foot-pumps provides an interesting alternative to chemical agents in the prevention of thomboembolic disease following major orthopaedic surgery procedures. Recent studies have suggested that simultaneous use of graduated compression stockings (GCS) may hinder the pneumatic compression effect of foot pumps. The hypothesis of this prospective study was that the use of foot-pumps without GCS does not affect the efficacy of DVT prophylaxis, and improves patient compliance. 846 consecutive patients admitted at a single institution undergoing total hip (THR) or knee replacement (TKR) were included in the study. The A-V Impulse System^® foot-pump units (Orthofix Vascular Novamedix, Andover, UK) was used in all patients. Forty-six patients discontinued the use of foot-pumps, leaving 400 patients who received foot-pumps in combination with GCS and 400 patients with foot pumps alone. Eleven patients of the stocking group (2.7%) and 9 patients of the no-stockings group (2.3%) developed postoperative symptomatic DVT (p=0.07). DVT was more frequent in TKR (10 of 364; 2.7%) than in THR (10 of 436; 2.3%). Non-fatal pulmonary embolism occurred in 4 patients out of 20 with symptomatic DVT, 2 each of the stockings and no stockings groups. The foot pump discontinuation rate of patients treated with stockings was 7%, versus 4% of patients treated without stockings (p< 0.05). In conclusion, management of patients with foot-pumps without GCS does not reduce efficacy of DVT prophylaxis after THR and TKR, and improves patient compliance.

Objectives

We aimed to examine the characteristics of deep venous flow in the leg in a cast and the effects of a wearable neuromuscular stimulator (geko; FirstKind Ltd) and also to explore the participants’ tolerance of the stimulator.

Abstract. INTRODUCTION. A paucity of literature exists regarding efficacy of lateral unloader bracing in treatment for pathologies effecting the lateral compartment of the knee. We evaluate patient outcomes following customised lateral unloader bracing (cLUB) in treatment of lateral compartment osteoarthritis (LCOA), lateral tibial plateau fractures (LTPF) and spontaneous osteonecrosis of knee (SONK). METHODS. Institutional study approval was obtained. All patients undergoing cLUB between January 2013 and January 2021 were included, and prospectively followed-up. Visual Analogue Scales (VAS), Oxford Knee Scores (OKS) and Knee Injury and Osteoarthritis Outcome Scores (KOOS) were assessed at brace fitting and final follow-up. Brace compliance, complications and surgical interventions were also collected. Statistical analysis utilised paired t-test. RESULTS. 71 patients (LCOA n=47, LTPF n=21, SONK n=3) were analysed. VAS, OKS and KOOS scores show significant improvements after bracing (p<0.05). Brace compliance was 90.5%. One patient developed a deep-vein thrombosis, 12.7% suffered skin irritation (n=5 LTPF/n=4 LCOA) managed with bio-skin calf sleeves, and brace intolerance occurred in 8.5% (n=6). Brace survivorship was 64.8% (n=46). Twenty-five patients underwent post-bracing surgery; LTPF n=2, LCOA n=22, SONK n=1. The mean time interval between brace fitting and arthroplasty for LKOA patients was 2.1 (range 0.5-4) years. CONCLUSION. Our cohort demonstrates good compliance and significant improvements with cLUB across acute and chronic pathologies. Surgery and associated risks were avoided in certain cases. Further research is required alongside a cost-analysis. However, with increasing disease burden and surgical waiting times cLUB could be a crucial component of management in selected knee pathology cases

Purpose. Topical application of tranexamic acid (TXA) to bleeding wound surfaces reduces blood loss in patients undergoing some major surgeries, without systemic complications. The objective of this study was to determine if TXA applied topically reduced postoperative bleeding and transfusion rates after primary total hip arthroplasty (THA) and primary bipolar hemiarthroplasty (BA). Methods. We retrospectively compared 77 patients undergoing hip arthroplasty surgery in which tranexamic acid was routinely used, to a group of 70 patients from a similar time frame prior to the introduction of tranexamic acid use. In the former group 40 patients had THA and 37 patients BA; in the latter group 35 patients underwent THA and 35 patients BA. In both THA and BA, the joint was bathed in TXA solution (at a concentration of 3.0 g TXA per 100 mL saline) at three points during the procedure. The primary outcome was blood loss calculated from the difference between the preoperative hemoglobin level and the corresponding lowest postoperative value or hemoglobin level prior to transfusion. Results. Postoperative transfusions decreased significantly with TXA, dropping from 50.0% to 27.5%, and from 63% to 48%, in the THA and BA groups, respectively. We also found significant reductions in hemoglobin loss and blood loss of 8 g/dL and 336 mL respectively for THAs and 6 g/dL and 176 mL respectively for BAs following the introduction of tranexamic acid. There was no difference in the rates of deep-vein thrombosis or pulmonary embolism between the two groups. Discussion and Conclusion. Topical application of TXA significantly reduces postoperative blood loss and transfusion risk in THA and BA, with no clinically important increase in complications being identified

Surgery for pelvic or acetabular fractures carries a high risk of deep-vein thrombosis (DVT). Reports indicate that fondaparinux is a more effective thromboprophylactic agent than low molecular weight heparin (LMWH) after major orthopaedic surgery. We prospectively evaluated a new protocol for DVT prophylaxis using fondaparinux. Patients and methods. One hundred and eight patients with pelvic or acetabular fractures were randomised to receive either fondaparinux or enoxaparin. Specific review points included the primary end-point of clinical deep vein thrombosis (DVT) or pulmonary embolism (PE) and any evidence of adverse effects such as bleeding or allergic reactions. Results. Two patients that received enoxaparin were found to have a DVT (3%) and one patient died from a PE (1%). There was no documented DVT or PE in patients that received fondaparinux. The mean number of units of blood transfused was significantly higher in the enoxaparin group and this was significant post-operatively (p<0.05). The current study supports that post-operative fondaparinux, in patients with pelvic and acetabular fractures, is more effective and equally safe to enoxaparin

Introduction: Unstable Lisfranc (tarsometatarsal) joint injuries are increasingly being treated by open reduction and internal fixation. Hypothesis: A good outcome is achievable by anatomical reduction and internal fixation of these injuries. Methods: This was a retrospective outcome-analysis involving 21 patients. Six were treated non-operatively. There sere eight ligamentous and seven ligamentous/osseous injuries. The patients’ outcomes were assessed with the use of the American Orthopaedic Foot and Ankle Society (AOFAS) midfoot score and the long-form Musculoskeletal Function Assessment (MFA) score. Results: The average follow-up was11 months. One patient developed a post-operative infection, and another developed a deep-vein thrombosis. The average AOFAS score was 71 and the average MFA score was 32. The study group as a whole sustained their injuries through low-energy trauma, therefore comparison with other studies should take this into account. Conclusions: Follow-up in this study was short an this was reflected in the scoring. Longer follow-up will allow a greater evaluation of final outcome

Aims: In major orthopedic surgery, fondaparinux provided a major benefit over enoxaparin, with an overall venous thromboembolsim (VTE) risk reduction of > 50% and similar safety profile regarding clinically relevant bleeding (leading to death or reoperation, or occurring in critical organ). The aim of the present study was to analyze this superior efficacy according to patients and surgery characteristics. Methods: In four phase III trials, the primary efficacy outcome was the VTE incidence up to day 11, defined as deep-vein thrombosis (DVT) detected by mandatory bilateral venography or documented symptomatic DVT or pulmonary embolism. Primary efficacy was further analyzed according to predefined categorical covariates using a logistic regression model. Results: Fondaparinux was more effective than enoxaparin irrespective of age, gender, obesity, the use of cement or surgery duration (odds reduction from −46.9% to −59.7% in favor of fondaparinux. Clinically relevant bleeding did not differ between the two groups according to predefine covariates. Conclusions: For VTE prevention in major orthopaedic surgery, the superiority of fondaparinux over enoxaparin was consistent irrespective of patient or surgery characteristics

Aims: Whether the use of elastic stockings (ES) on top of pharmacological thromboprophylaxis is beneficial remains debated. In a worldwide phase III program including 7344 patients in major orthopaedic surgery, fondaparinux, the first synthetic selective factor Xa inhibitor, demonstrated a substantial benefit over enoxaparin in preventing venous thromboembolism (VTE); risk reduction > 50% without increasing clinically relevant bleeding. The aim of this study was to evaluate the influence of ES on this superior efficacy of fondaparinux. Methods: In all four randomized, double-blind trials, comparing a once daily 2.5 mg s.c. injection of fondaparinux to enoxaparin, the primary efficacy outcome was VTE up to day 11, defined as deep-vein thrombosis (DVT) detected by mandatory bilateral venography, or documented symptomatic DVT or pulmonary embolism. A post-hoc analysis on primary efficacy was performed according to the use of ES. Results: The table shows VTE incidences by day 11 without and with ES. Conclusions: In major orthopaedic surgery, fondaparinux showed a similar superior efficacy over enoxaparin in patients with and without ES, indicating that ES did not influenced the major benefit of this new agent. An additive effect of ES in enoxaparin-treated patients cannot be excluded but the effect is insufficient compared with fondaparinux alone

A consecutive group of 150 patients undergoing primary TKA performed by a single surgeon using single prosthesis were studied prospectively. The purpose of this study was to compare the clinical and radiographic results of TKA in obese and non-obese patients. The patients were categorized into two groups: non-obese (body mass index (BMI < 30 kg/m2) and obese (BMI > 30 to 40 kg/m2). The Primary outcome measures: SF-12 and WOMAC scores were used as generic outcome measures, and the Knee Society scores were used to assess clinical outcome of TKA. The scores were done pre-operatively and at 1, 3 and 5 years post-operatively. Secondary outcome measures included patellar position, anterior knee pain, infections, revision rates, deep-vein thrombosis and pulmonary embolism, length of hospital stay and mortality. Seventeen patients have died since and none were lost to follow-up. Obese patients had less benefit and overall KSS outcome scores at one year (p-value 0.05) but had similar scores at 3 and 5 years (p-values 0.3 and 0.5). Pre-operative WOMAC and SF-12 scores were significantly worst in obese patients (p-value 0.009 and 0.005) but had the similar outcome at 1, 3 and 5 years. Three patients in the series required revision surgery for infection. One patient had DVT and another had PE post-operatively. Overall obese patients although had lower KSS scores at one year but had better outcome in SF-12 and WOMAC scores at one year. There was no difference at 3 and 5 years. We found that body weight did not influence adversely the outcome of TKA at medium term

On the basis of observations made in recent years, it can be inferred that the incidence of venous thromboembolism (VTE) in Japan is as high as that in Western countries. Since 2007, the use of fondaparinux for the prophylaxis of VTE following lower-limb orthopedic surgery has been approved for Japanese patients. This study was performed with an aim to investigate the safety and efficacy of fondaparinux for the prevention of VTE following hip surgery in Japanese patients. From June 2007 to August 2008, we evaluated 141 consecutive patients (148 hips; average age, 65.6) undergoing total hip replacement (THR), consisted of cementless minimally invasive surgery, and hip fracture surgery (HFS), consisted of open reduction and internal fixation or bipolar hemiarthroplasty. We mainly used 2.5 mg of fondaparinux for a period extending up to 14 days. We estimated the symptomatic VTE and asymptomatic deep-vein thrombosis (DVT) rates in patients by ultrasonography performed on preoperative and postoperative day 3. In addition, we evaluated the pre-operative and postoperative plasma D-dimer levels on days 3, 7, and 14. We determined that both the preoperative and postoperative incidence of symptomatic VTE was 0%. A D-dimer value of 20 ug/ml or higher was not observed on preoperative days 3 and 7; however, this value was observed in 2 hips on postoperative day 14. The incidence of asymptomatic DVT was observed to be 0.8% preoperatively and 4% postoperatively. In particular, the corresponding value following HFS was observed to be 7.7% preoperatively. The incidence of the hemorrhagic event was observed to be 14.9%. Bleeding was mostly observed in the surgical and drainage areas. An overall major bleeding incidence of 0.7% (1 patient) was observed. The corresponding value in patients in whom the administration of fondaparinux was discontinued by day 14 was 18.9%. The study results indicate that fondaparinux is useful in Japanese patients for the prevention of VTE following hip surgery. However, the administration of this drug should be accompanied by additional measures to prevent the associated side effect of bleeding

Introduction: The increasing utilization of total hip arthroplasty and the increasing life expectancy have brought an increasing incidence of revision hip arthroplasty. With severe acetabular, revision surgery with the use of standard cemented or press-fitted components is inadequate for fixation. In these cases the use of proximal femoral allograft can restore the deficiency. Purpose: To present a new technique and preliminary results of revision total hip arthroplasty using proximal femoral allograft prosthetic composites for massive ace-tabular bone loss. The technique uses the natural vector of forces in the intertrochanteric region in an opposite direction at the acetabular defect. Methods: From June 2000 to July 2001, seven patients underwent reconstruction of massive acetabular defects with proximal femoral allograft bone. The etiologies for bone loss were infection in 2 patients, aseptic loosening in 4 and acetabular protrusion in 2 patients. In 4 hips there were also femoral defects that was reconstructed with allograft. The average age of the patients was 69.8 years. All patients were wheel chair bound prior to surgery. Harris Hip Score was used to assess preoperative and follow-up function level. Results: Harris Hip Score improved significantly in all patients. All patients are ambulatory at follow-up. Complications included 2 dislocation and 2 deep-vein thrombosis. No allograft resorbtion was noted at follow-up. Conclusions: The proximal femoral allograft provides a solid construct for the acetabular cup in large acetabular bone defects. Although failure and complication rates might be higher than revision procedures with lesser bone defects, this reconstructive option for massive ace-tabular defects dramatically improves a patient’s function level

Background: Data on thromboembolic complications (TEC) following major orthopaedic surgery are generally obtained retrospectively from registries or prospectively from large industry-sponsored international multicentre trials. However, the results may differ from those observed in unselected patients in routine operations performed by orthopaedic surgeons. The purpose of the ESMOS study was to describe the number and time of onset of serious symptomatic arterial and venous TEC within 90 days after surgery in an unselected population of patients undergoing total hip replacement (THR). Patients and methods: A total of 500 (430 primary THR and 70 revision THR) consecutive patients were included in the study performed between January 2004 and May 2005 in Frederiksborg County (Denmark). They were to be followed for 90 days after surgery. Patients were interviewed before surgery for medical history and on days 5 (while in hospital) and 90 (by telephone call) for signs and symptoms of acute myocardial infarction (AMI), pulmonary embolism (PE), deep-vein thrombosis (DVT), transitory cerebral ischemia (TCI)/stroke and retinal vein thrombosis (RVT). The validity of the events was confirmed using files from hospital, general practitioner and international criteria. Results: Overall, 498 patients were followed-up for 90 days, 2 patients having withdrawn consent. In-hospital pharmacological thromboprophylaxis was performed in 499 patients. Twenty-four patients (4.8%) experienced at least one serious TEC up to day 90: 2 (0.4%) patients died from surgical-related complications (no autopsy was performed); 1 (0.2%) patient experienced AMI, 5 (1.0%) had PE, 10 (2.0%) DVT, 4 (0.8%) TCI, and 2 (0.4%) RVT. Moreover, 2 patients experienced two TEC: AMI followed by TCI in a first patient, PE and TCI in a second patient. The first event occurred up to day 5 in 9 patients (38%) and after day 5 in 15 patients (62%). Five patients (1%) had clinically relevant bleeding complications: 3 patients had a single, minor, upper gastrointestinal bleeding episode while in hospital, one patient developed a huge expanding haematoma at the operation site treated with hip spica and another patient a peritoneal haematoma leading to re-operation. Conclusion: This study performed in an unselected population clearly shows that THR still results in serious TEC in spite of a wide use of modern anaesthesia techniques, thrombosis prophylaxis and early mobilisation. In the future, we need to better identify at-risk patients in order to optimise their management, in particular post-discharge care, and reduce the risk of serious TEC

Aims

The purpose of this study was to examine the efficacy and safety of carbazochrome sodium sulfonate (CSS) combined with tranexamic acid (TXA) on blood loss and inflammatory responses after primary total hip arthroplasty (THA), and to investigate the influence of different administration methods of CSS on perioperative blood loss during THA.

Aims

The primary aim of this study was to identify independent predictors associated with nonunion and delayed union of tibial diaphyseal fractures treated with intramedullary nailing. The secondary aim was to assess the Radiological Union Scale for Tibial fractures (RUST) score as an early predictor of tibial fracture nonunion.

The August 2012 Foot & Ankle Roundup³⁶⁰ looks at: calcaneocuboid distraction arthrodesis with allograft for acquired flatfoot; direct repair of the plantar plate; thromboembolism after fixation of the fractured ankle; weight loss after ankle surgery; Haglund’s syndrome and three-portal endoscopic surgery; Keller’s procedure; arthroscopy of the first MTPJ; and Doppler spectra in Charcot arthropathy.

Over recent years hip arthroscopic surgery has evolved into one of the most rapidly expanding fields in orthopaedic surgery. Complications are largely transient and incidences between 0.5% and 6.4% have been reported. However, major complications can and do occur. This article analyses the reported complications and makes recommendations based on the literature review and personal experience on how to minimise them.